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Abstract: BACKGROUND: Live vaccines are generally contraindicated on immunosuppressive therapy
due to safety concerns. However, data are limited to corroborate this practice. OBJECTIVES: To esti-
mate the safety of live vaccinations in patients with immune-mediated inflammatory diseases (IMID) or
solid organ transplantation (SOT) on immunosuppressive treatment and in patients after bone-marrow
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RIA: Randomized trials, observational studies and case reports. POPULATION: Patients with IMID or
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(YF), varicella vaccine (VV), herpes zoster (HZ), oral typhoid, oral polio, rotavirus, Bacillus Calmette-
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and 64 articles were included: 40 on IMID, 16 on SOT and 8 on BMT patients. In most studies, the ad-
ministration of live vaccines was safe. However, some serious vaccine-related adverse events occurred. 32
participants developed an infection with the vaccine strain; in most cases the infection was mild. However,
in two patients fatal infections were reported: a patient with RA/SLE overlap who started MTX/dex-
amethasone treatment four days after the YFV developed a yellow fever vaccine-associated viscerotropic
disease (YEL-AVD) and died. The particular vaccine lot was found to be associated with a more than
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received the BCG vaccine at the age of three months and developed disseminated BCG infection and
died. An immunogenicity assessment was performed in 43 studies. In most cases the patients developed
satisfactory seroprotection rates. In the IMID group, YFV and VV demonstrated high seroconversion
rates. MTX and tumor necrosis factor inhibitory therapy appeared to reduce immune responses to VV
and HZ vaccine, but not to MMR and YF-revaccination. Seroconversion in SOT and BMT patients
showed mostly higher rates for rubella than for measles, mumps and varicella. LIMITATIONS: Risk of
bias was high in the majority of studies since 39 of them were observational and 17 were case series/case
reports. Only eight studies were randomized trials. BMT patient numbers included in this review were
low. CONCLUSIONS: Although live vaccinations were safe and sufficiently immunogenic in most studies,
some serious reactions and vaccine-related infections were reported in immunosuppressed IMID and SOT
patients. Apart from mild vaccine-related infections MMR and VV vaccines were safe when administered
less than two years after BMT. IMPLICATIONS OF KEY FINDINGS: Until further data are available,
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DOI: https://doi.org/10.1016/j.vaccine.2017.01.048
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-143879
Journal Article
Accepted Version
Originally published at:
Croce, Evelina; Hatz, Christoph; Jonker, Emile F; Visser, L G; Jaeger, Veronika K; Bühler, Silja (2017).
Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory
diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of
randomized trials, observational studies and case reports. Vaccine, 35(9):1216-1226.
DOI: https://doi.org/10.1016/j.vaccine.2017.01.048
2
	 1	
Title		1	
Safety	 of	 live	 vaccinations	 on	 immunosuppressive	 therapy	 in	 patients	 with	 immune-mediated	2	
inflammatory	 diseases,	 solid	 organ	 transplantation	 or	 after	 bone-marrow	 transplantation	 –	 a	3	
systematic	review	of	randomized	trials,	observational	studies	and	case	reports	4	
	5	
Authors	6	
Evelina	Croce	a	7	
Christoph	Hatz	a,b,c	8	
Emile	F.	Jonker	d	9	
L.	G.	Visser	d	10	
Veronika	K.	Jaeger	e	11	
Silja	Bühler	a,*	12	
	13	
a	Department	of	Public	Health,	Division	of	Infectious	Diseases	/	Travel	Clinic,	Epidemiology,	14	
Biostatistics	and	Prevention	Institute,	Hirschengraben	84,	8001	Zurich,	Switzerland.	Phone:	+41	44	15	
634	4631,	Fax:	+41	44	634	4984	16	
b	Department	of	Medicine	and	Diagnostics,	Swiss	Tropical	and	Public	Health	Institute,	Socinstrasse	17	
57,	4051	Basel,	Switzerland.	Phone:	+41	61	284	81	11,	Fax:	+41	61	284	81	01	18	
c	University	of	Basel,	Switzerland,	Petersplatz	1,	4003	Basel,	Switzerland,	Phone:	+41	61	284	81	11,	19	
Fax:	+41	61	284	81	01	20	
	 2	
c	Department	of	Infectious	Diseases,	Leiden	University	Medical	Center,	Leiden,	The	Netherlands,	1	
Phone:	+31	71	5262613,	Fax:	+31	71	5266758	2	
e	Department	of	Rheumatology,	Basel	University	Hospital,	Petersgraben	4,	4031	Basel,	Switzerland.	3	
Phone:	+41	61	556	50	18,	Fax:	+41	61	265	90	21		4	
	5	
*	Corresponding	author	6	
	7	
	8	
	9	
	10	
	11	
	12	
	13	
	14	
	15	
	16	
	17	
	18	
	19	
	20	
	21	
	22	
	23	
	24	
	25	
	26	
	27	
	28	
	29	
	30	
	31	
	32	
	 	33	
	 3	
Abstract	1	
Background:	 Live	 vaccines	 are	 generally	 contraindicated	 on	 immunosuppressive	 therapy	 due	 to	2	
safety	concerns.	However,	data	are	limited	to	corroborate	this	practice.	3	
Objectives:	 To	 estimate	 the	 safety	 of	 live	 vaccinations	 in	 patients	 with	 immune-mediated	4	
inflammatory	diseases	(IMID)	or	solid	organ	transplantation	(SOT)	on	immunosuppressive	treatment	5	
and	in	patients	after	bone-marrow	transplantation	(BMT).	6	
Data	 Sources:	 A	 search	 was	 conducted	 in	 electronic	 databases	 (Cochrane,	 Pubmed,	 Embase)	 and	7	
additional	literature	was	identified	by	targeted	searches.		8	
Eligibility	criteria:	Randomized	trials,	observational	studies	and	case	reports.			9	
Population:	Patients	with	IMID	or	SOT	on	immunosuppressive	treatment	and	BMT	patients	<2	years	10	
after	transplantation.	11	
Intervention/vaccinations	looked	at:	Live	vaccinations:	mumps,	measles,	rubella	(MMR),	yellow	fever	12	
(YF),	varicella	vaccine	(VV),	herpes	zoster	(HZ),	oral	typhoid,	oral	polio,	rotavirus,	Bacillus	Calmette–13	
Guérin	(BCG),	smallpox.	14	
Data	extraction:	One	author	performed	the	data	extraction	using	predefined	data	fields.	It	was	cross-15	
checked	by	two	other	authors.	16	
Results:	7,305	articles	were	identified	and	64	articles	were	included:	40	on	IMID,	16	on	SOT	and	8	on	17	
BMT	patients.	 In	most	studies,	the	administration	of	 live	vaccines	was	safe.	However,	some	serious	18	
vaccine-related	 adverse	 events	 occurred.	 32	 participants	 developed	 an	 infection	 with	 the	 vaccine	19	
strain;	in	most	cases	the	infection	was	mild.	However,	in	two	patients	fatal	infections	were	reported:	20	
a	patient	with	RA/SLE	overlap	who	started	MTX/dexamethasone	tretament	four	days	after	the	YFV	21	
developed	a	yellow	fever	vaccine-associated	viscerotropic	disease	(YEL-AVD)	and	died.	The	particular	22	
vaccine	lot	was	found	to	be	associated	with	a	more	than	20	times	risk	of	YEL-AVD.	One	infant	whose	23	
mother	was	 under	 infliximab	 treatment	 during	 pregnancy	 received	 the	 BCG	 vaccine	 at	 the	 age	 of	24	
three	months	and	developed	disseminated	BCG	 infection	and	died.	An	 immunogenicity	assessment	25	
	 4	
was	performed	in	43	studies.	In	most	cases	the	patients	developed	satisfactory	seroprotection	rates.	1	
In	 the	 IMID	 group,	 YFV	 and	VV	 demonstrated	 high	 seroconversion	 rates.	MTX	 and	 tumor	 necrosis	2	
factor	 inhibitory	 therapy	 appeared	 to	 reduce	 immune	 responses	 to	VV	and	HZ	 vaccine,	 but	not	 to	3	
MMR	and	YF-revaccination.	Seroconversion	in	SOT	and	BMT	patients	showed	mostly	higher	rates	for	4	
rubella	than	for	measles,	mumps	and	varicella.	5	
Limitations:	Risk	of	bias	was	high	in	the	majority	of	studies	since	39	of	them	were	observational	and	6	
17	were	case	series/case	reports.	Only	eight	studies	were	randomized	trials.	BMT	patient	numbers	7	
included	in	this	review	were	low.		8	
Conclusions:	 Although	 live	 vaccinations	 were	 safe	 and	 sufficiently	 immunogenic	 in	 most	 studies,	9	
some	serious	reactions	and	vaccine-related	infections	were	reported	in	immunosuppressed	IMID	and	10	
SOT	 patients.	 Apart	 from	 mild	 vaccine-related	 infections	 MMR	 and	 VV	 vaccines	 were	 safe	 when	11	
administered	less	than	two	years	after	BMT.		12	
Implications	 of	 key	 findings:	 Until	 further	 data	 are	 available,	 live	 vaccinations	 under	 most	13	
immunosuppressive	treatments	should	only	be	administered	after	a	careful	risk	benefit	assessment	14	
of	medications	and	dosages.		15	
Funding:	None.	16	
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Introduction	1	
	2	
Immunizations	are	an	important	means	for	preventing	infectious	diseases	in	healthy	individuals	and	3	
especially	 in	 vulnerable	 patient	 groups	 with	 immunocompromising	 conditions.	 However,	 live	4	
vaccinations	contain	an	attenuated	vaccine	strain,	which	has	the	theoretical	potential	to	revert	to	the	5	
original	 pathogenic	 form	 and	 to	 induce	 infection	 by	 the	 vaccine	 strain,	 particularly	 in	6	
immunocompromised	 individuals.	 Serious	 infections	with	 the	 vaccine	 strain	 and	 even	 deaths	 have	7	
occurred	in	HIV	patients,	leukemia	patients	and	patients	with	inherited	immunodeficiencies	[1–4].	8	
The	number	of	 individuals	 treated	with	 immunosuppressive	medications	due	 to	 immune-mediated	9	
inflammatory	 diseases	 (IMID),	 solid	 organ	 transplantation	 (SOT)	 or	 patients	 after	 bone-marrow	10	
transplantation	(BMT)	has	grown	over	the	last	decades	[5].	Clinicians	are	increasingly	exposed	to	the	11	
dilemma	 on	 whether	 an	 immunosuppressed	 patient	 can	 receive	 a	 live	 vaccine	 –	 which	 is	 very	12	
important	as	severe	infections	with	infections	preventable	by	live	vaccinations	such	as	measles	and	13	
varicella	 can	occur	on	 immunosuppressive	 therapy	 [6,7].	On	 the	other	hand,	 the	 live	 vaccine	 itself	14	
may	 impose	 a	 danger	 to	 the	 immunosuppressed	 individual.	 Furthermore,	 vaccines	 may	 be	 less	15	
effective	when	administered	to	an	impaired	immune	system	[8].	16	
To	date,	live	vaccines	are	contraindicated	under	most	immunosuppressive	therapies.	However,	data	17	
are	generally	scarce.	Over	the	last	few	years	efforts	have	been	made	to	evaluate	the	safety	of	some	18	
live	 vaccines	 in	 selected	 immunosuppressed	 individuals	 by	 conducting	 both,	 retrospective	 and	19	
prospective	 studies.	 Further	 data	 have	 become	 available	 as	 live	 vaccines	 were	 occasionally	20	
administered	inadvertently	or	after	a	careful	risk-benefit	assessment	to	individual	patients.		21	
In	 this	 systematic	 review,	we	 aim	 to	 provide	 an	 overview	 on	 the	 results	 of	 published	 randomized	22	
trials,	observational	 studies	and	case	 reports	on	 live	vaccinations	 in	patients	with	 IMIDs	or	SOT	on	23	
immunosuppressive	therapy	as	well	as	BMT	patients	who	received	a	live	vaccine	less	than	two	years	24	
after	 receiving	 the	BMT.	 Live	 vaccines	are	generally	 accepted	after	 this	 2	 year	 time	period	 in	BMT	25	
	 6	
patients	if	no	immunosuppressive	therapy	is	given	and	no	GvHD	is	present	[9].	Our	primary	objective	1	
is	to	examine	the	safety	of	the	live	vaccinations	(mumps,	measles,	rubella	(MMR),	yellow	fever	(YF),	2	
varicella	vaccine	(VV),	herpes	zoster	(HZ),	oral	typhoid,	oral	polio,	rotavirus,	Bacillus	Calmette–Guérin	3	
(BCG),	 smallpox)	 in	 patients	 on	 immunosuppressive	 treatment	 with	 an	 IMID	 or	 SOT	 as	 well	 as	4	
patients	less	than	two	years	after	BMT.	This	includes	the	assessment	(i)	of	systemic	or	local	vaccine	5	
reactions	 (ii)	 of	 the	 risk	 of	 infection	 with	 the	 attenuated	 vaccine	 strain,	 and	 (iii)	 on	 whether	 live	6	
vaccinations	 are	 associated	 with	 relapses/worsening	 of	 the	 underlying	 disease	 or	 organ	 rejection.	7	
Our	 secondary	 objectives	 are	 to	 examine	 the	 immunogenicity	 and	 the	 clinical	 protection	 of	 live	8	
vaccinations	in	these	patients.		9	
	10	
11	
	 7	
Methods	1	
Eligibility	criteria	for	study	inclusion	2	
Population:	Patients	of	any	age	with	an	IMID	or	SOT	who	were	on	immunosuppressive	treatment	at	3	
the	 time	of	 vaccination	as	well	 as	patients	 less	 than	 two	years	after	BMT	were	considered.	As	 live	4	
vaccines	are	generally	accepted	two	years	after	BMT	if	no	immunosuppressive	therapy	is	given	and	5	
no	 GvHD	 is	 present	 publications	 on	 live	 vaccines	 more	 than	 two	 years	 after	 BMT	 were	 not	6	
considered.	7	
Studied	 Vaccinations:	 Live	 attenuated	 vaccinations	 (MMR,	 YF,	 VV,	 HZ,	 oral	 typhoid,	 oral	 polio,	8	
rotavirus,	BCG,	smallpox).		9	
Outcomes:	 Our	 primary	 outcome	 measure	 is	 the	 safety	 of	 live	 vaccinations;	 this	 includes	 the	10	
assessment	(i)	of	systemic	or	 local	vaccine	reactions	(ii)	of	the	risk	of	 infection	with	the	attenuated	11	
vaccine	 strain,	and	 (iii)	on	whether	 live	vaccinations	are	associated	with	 relapses/worsening	of	 the	12	
underlying	disease	or	organ	rejection.	The	secondary	outcome	measures	are	the	immunogenicity	and	13	
clinical	 protection	 of	 live	 vaccinations	 in	 patients	 with	 the	 conditions	 defined	 above.	 To	 assess	14	
immunogenicity	we	 included	humoral	 immune	responses	 (antibody	concentrations,	 seroconversion	15	
rates)	 and	 cellular	 responses,	 depending	 on	 the	 available	 information	 in	 the	 studies.	 As	 often	 no	16	
control	group	was	studied	we	focused	on	clinical	protection	and	not	on	efficacy	or	effectiveness	of	17	
vaccinations.		18	
Included	Study	Designs:	Randomized	trials,	observational	studies	and	case	reports.	19	
Information	Sources	20	
The	 Cochrane,	 Pubmed,	 Embase	 databases	 were	 searched	 without	 applying	 time	 restrictions.	21	
Unpublished	 (grey)	 literature	 (unpublished	 reports,	 conference	 abstracts)	 was	 retrieved	 through	22	
targeted	 website	 searches	 of	 relevant	 organizations	 and	 international	 conferences	 dealing	 with	23	
vaccination,	 infectious	 diseases,	 IMIDs,	 SOT	 and	 BMT,	 i.e.	 European	 League	 Against	 Rheumatism,	24	
	 8	
Centers	for	Disease	Control	and	Prevention,	Infectious	Diseases	Society	of	America,	American	College	1	
of	Rheumatology,	European	Society	for	Organ	Transplantation,	American	Society	of	Transplantation,	2	
European	 Society	 for	 Blood	 and	 Marrow	 Transplantation,	 American	 Society	 for	 Bone	 Marrow	3	
Transplantation.	 Additional	 articles	were	 identified	 through	 reference	 lists	 of	 selected	 papers.	 The	4	
search	was	run	on	March	23rd	2014.	A	limited	update	search	was	run	on	January	22nd	2016.		5	
Search	 terms	were	 peer	 reviewed	 during	 the	 development	 process.	 The	 search	 terms	 in	 Figure	 1	6	
were	 used	 in	 combination	 to	 search	 the	 databases.	 Corresponding	Medical	 Subject	 Headings	 and	7	
Embase	subject	headings	were	searched	for.	8	
Study	selection	9	
Two	 review	 authors	 performed	 eligibility	 assessment	 based	 on	 titles,	 key	 words,	 and	 abstracts	10	
independently	 (SB	 and	 VKJ).	 Disagreements	 between	 review	 authors	were	 resolved	 by	 consensus.	11	
One	 review	 author	 conducted	 the	 eligibility	 assessment	 (EC)	 based	 on	 the	 full	 article;	 this	 was	12	
checked	by	two	other	review	authors	(SB	and	VKJ).	If	authors	published	several	studies	on	the	same	13	
subject	(e.g.	varicella	vaccination	in	stem	cell	transplantation)	we	compared	sample	sizes,	outcomes	14	
and	time	frames	of	study	conduct	to	avoid	double	counting.	15	
Data	collection	process	16	
A	data	extraction	sheet	was	piloted	on	five	randomly-selected	studies	and	was	refined	accordingly.	17	
Data	extraction	was	performed	by	one	author	(EC)	and	checked	by	two	other	authors	(SB	and	VKJ).	In	18	
case	of	disagreement,	a	consensus	was	sought	by	discussion	between	the	three	authors.	In	10	cases,	19	
study	authors	were	contacted	to	receive	further/clarifying	information.	Seven	authors	answered	and	20	
in	six	cases	 the	 relevant	 information	could	be	 retrieved.	 In	 three	cases	 the	author	did	not	 respond	21	
and	 it	 could	 not	 be	 clarified	whether	 the	 patients	 were	 treated	with	 immunosuppressive	 therapy	22	
during	the	immunization.	These	three	articles	were	excluded.		23	
Data	items	24	
	 9	
Information	from	each	record	was	extracted	on	year	of	publication,	year	of	study	conduct,	country,	1	
study	 design,	 number	 of	 participants,	 enrolment	 of	 controls,	 number	 of	 vaccine	 doses,	 underlying	2	
disease,	 immunosuppressive	medication,	 primary	 vaccine	 dose	 or	 secondary/revaccination	 vaccine	3	
doses,	 vaccine	 reaction	 (local	 or	 systemic),	 infection	 through	 vaccine	 strain,	 flare	 of	 underlying	4	
disease	 (IMID)	 or	 transplant	 rejection	 (SOT/BMT),	 immunogenicity	 assessment	 performed,	 test	 for	5	
immunogenicity	assessment,	 time	point	 for	 immunogenicity	assessment,	 results	of	 immunogenicity	6	
assessment,	clinical	protection	assessment	performed,	duration	of	 follow-up	 for	clinical	protection,	7	
results	 of	 clinical	 protection	 assessment,	 conclusion	 (see	 supplementary	 file).	 If	 a	 live	 vaccine	was	8	
administered	 to	 a	 seronegative	 patient	 it	 was	 defined	 as	 a	 “primary	 vaccination”.	 If	 a	 second	9	
vaccination	was	given	or	 if	patients	were	known	 to	be	 seropositive	at	 the	 time	of	 vaccination,	 the	10	
vaccination	was	defined	as	“secondary	vaccination”	or	“re-immunization”.		11	
	12	
	 	13	
	 10	
Results	1	
Study	selection	2	
7,290	 articles	 were	 identified	 through	 database	 searching	 and	 15	 articles	 were	 identified	 through	3	
other	sources.	After	removal	of	duplicates,	7,187	articles	remained.	550	articles	were	left	after	title	4	
and	keyword	screening	and	105	 (IMID	n=64,	BMT	n=20,	SOT	n=21)	articles	were	 left	after	abstract	5	
screening	(Figure	2).	The	full-text	of	these	articles	were	assessed	for	eligibility	and	finally	64	articles	6	
were	included	in	this	systematic	review	(see	supplementary	file	for	details	on	included	studies).		7	
Of	 these,	 40	 (YF	 n=9	 (n=8	 in	 adults,	 n=1	 in	 children	 and	 adults),	MMR	 n=6	 (n=1	 in	 adults,	 n=5	 in	8	
children),	 varicella	 n=12	 (n=3	 in	 adults,	 n=9	 in	 children,	 n=1	 in	 children	 and	 adults),	 HZ	 n=8	 (all	 in	9	
adults),	polio	n=1	(adult),	BCG	n=4	(n=2	in	adults,	n=2	in	children),	live	typhoid	n=1	(adult),	smallpox	10	
n=1	(adult))	were	conducted	in	IMID	patients.	16	studies	(YF	n=2	(n=1	in	adults,	n=1	in	children	and	11	
adults),	MMR	n=7	(all	in	children),	varicella	n=11	(n=2	in	adults,	n=9	in	children),	BCG	n=1	(children))	12	
were	 identified	 in	 SOT	patients	 and	 eight	 (MMR	n=4	 (n=2	 in	 children,	 n=2	 in	 children	 and	 adults),	13	
varicella	 n=5	 (n=1	 in	 adults,	 n=2	 in	 children,	 n=2	 in	 children	 and	 adults))	 in	 BMT	 patients.	 Some	14	
studies	evaluated	several	live	vaccines.	No	study	on	rotavirus	vaccination	was	identified.	In	one	study	15	
the	 participants	 (IMID	 patients)	were	 vaccinated	 simultaneously	 against	 YF,	MMR	 and	 varicella.	 In	16	
five	 studies	 (SOT	 patients)	 the	 participants	 were	 vaccinated	 against	 MMR	 and	 varicella	17	
simultaneously.	41	full-text	articles	were	excluded	because	patients	were	not	on	immunosuppressive	18	
therapy	at	time	point	of	vaccination	(IMID	or	SOT,	n=15),	administration	of	live	vaccine	later	than	two	19	
years	after	BMT	(n=11),	no	original	work	(n=12),	the	results	were	already	presented	in	other	articles	20	
(n=2),	or	because	of	an	additional	inherited	immunodeficiency	of	the	vaccinated	patient	(n=1).	Out	of	21	
the	64	included	articles,	eight	were	randomized	controlled	trials	(RCTs),	39	observational	studies	and	22	
17	case	 series/reports.	RCTs	were	only	 identified	 in	 the	 IMID	group	 (varicella	n=5,	HZ	n=1,	YF	n=1,	23	
MMR	n=1).	24	
Study	characteristics	25	
	 11	
A	total	of	21,082	patients	received	a	live	vaccine	in	the	studies,	which	were	published	between	1977	1	
and	2016.	Studies	were	conducted	in	18	different	countries	including	USA	(n=18),	Brazil	(n=13),	Japan	2	
(n=6)	 and	 Germany	 (n=4).	 As	 some	 patients	 received	 several	 live	 vaccines	 concomitantly	 the	3	
presented	numbers	may	not	add	up.		4	
Immune	mediated	inflammatory	diseases	5	
Most	of	the	patients	(n=20,556)	had	an	IMID.	Of	these,	19,630	patients	received	an	HZ,	474	an	MMR,	6	
233	a	YF,	202	a	varicella,	10	an	oral	 typhoid,	5	a	BCG,	one	a	 live	poliomyelitis	 and	one	a	 smallpox	7	
vaccination.		8	
The	most	 frequently	 represented	disease	 categories	 in	 the	 IMID	group	are	 summarized	 in	Table	1.	9	
The	 participants	 in	 the	 IMID	 group	were	 under	 22	 different	 immunosuppressive	medications.	 The	10	
most	 common	medication	 in	 this	 group	was	 glucocorticoids	 (n=384)	with	 a	 prednisone-equivalent	11	
dosage	 range	of	2.5-35mg/day,	 followed	by	methotrexate	 (MTX,	n=268)	with	a	dosage	 range	of	5-12	
27mg/m2/week.	 98	 patients	 in	 the	 IMID	 group	 were	 treated	 with	 a	 combination	 therapy;	 218	13	
received	a	monotherapy	with	a	biological,	39	received	a	combination	therapy	with	a	biological.	633	14	
patients	received	herpes	zoster	vaccine	(HZV)	under	biological	therapy.	 It	was	unclear	whether	this	15	
was	 a	 mono-	 or	 a	 combination	 therapy.	 In	 this	 study	 the	 medication	 was	 only	 reported	 in	16	
7,780/18,683	patients.	So	numbers	of	patients	with	HZV	on	 immunosuppressive	 therapy	may	have	17	
been	 higher	 [10].	 In	 the	 IMID	 group,	 in	 18	 studies	 primary	 vaccinations	 were	 administered,	 in	 13	18	
studies	 secondary	 doses	 were	 given.	 In	 six	 studies	 a	 primary	 and	 a	 secondary	 vaccination	 were	19	
administered	and	in	three	studies	it	was	unknown	whether	a	primary	or	a	secondary	vaccination	was	20	
given.		21	
	22	
SOT	23	
339	SOT	patients	with	 live	vaccinations	were	 identified;	192	were	vaccinated	against	varicella,	172	24	
against	MMR,	20	against	YF,	and	24	received	the	BCG	vaccine.		25	
	 12	
Of	the	339	SOTs,	271	were	liver	transplants,	62	kidney	transplants,	four	heart	transplants,	one	small	1	
bowel	transplant,	and	one	liver	and	small	bowel	transplant.	The	SOT	patients	were	treated	with	eight	2	
different	 immunosuppressive	 medications.	 The	 most	 frequently	 used	 medication	 was	 tacrolimus	3	
(TAC,	n=134,	2.4-10ng/ml	 in	 serum),	 followed	by	cyclosporine	A	 (CSA,	n=56)	with	a	dosage	 range	4	
from	30-120ug/l;	70	 transplanted	participants	were	under	a	combination	 therapy.	 In	 seven	studies	5	
patients	 received	 a	 primary	 vaccination,	 in	 one	 study	 only	 revaccinations	were	 given	 and	 in	 eight	6	
studies	the	patients	received	a	primary	vaccination	as	well	as	a	secondary	vaccination.		7	
BMT	8	
Only	 a	 small	 part	 of	 the	 participants	were	patients	with	BMT	 (n=187).	 Of	 these,	 152	 received	 an	9	
MMR	 vaccination	 and	 38	 received	 a	 VV.	 The	 underlying	 diseases	 of	 BMT	 patients	 are	 specified	 in	10	
Table	2.	All	BMT	patients	(n=38)	who	received	VV,	were	not	on	current	immunosuppressive	therapy.	11	
27	patients	who	received	an	MMR	immunization	were	treated	with	an	immunosuppressive	therapy	12	
at	 vaccination	 (CSA	 n=12,	 CSA/prednisone	 n=11;	 prednisone	 n=2,	 mycophenolate-mofetil	 (MMF)	13	
n=2).	 In	one	study,	seven	BMT	patients	(MMR	vaccination	n=7,	VV	n=3)	took	a	calcineurin	 inhibitor	14	
and	 MMF	 as	 graft	 versus	 host	 disease	 (GvHD)	 prophylaxis	 [11].	 In	 five	 studies	 only	 primary	15	
vaccinations	were	administered	and	in	three	studies	the	patients	received	a	primary	and	a	secondary	16	
immunization.		17	
Results	of	individual	studies	18	
Safety	19	
Local	or	systemic	vaccine	reactions	20	
Out	of	the	21,082	involved	participants,	local	or	systemic	vaccine-associated	adverse	reactions	were	21	
observed	 in	 280	 patients	 (1.3%):	 207/20,556	 (1.0%)	 in	 the	 IMID	 group,	 61/339	 (18.0%)	 in	 the	 SOT	22	
group	and	12/187	in	the	BMT	group	(6.4%).	Most	frequent	adverse	reactions	(n=269)	were	mild	such	23	
as	 injection-site	 pain,	 headache,	 fatigue,	 myalgia,	 fever,	 arthralgia,	 and	 nausea.	 Serious	 adverse	24	
	 13	
events	(SAEs)	were	reported	by	11	participants	(Table	3).		1	
In	one	study	SAEs	were	reported	in	11	IMID	patients	under	prednisone	treatment	who	received	HZV	2	
[12].	However,	SAEs	in	the	placebo	group	were	as	frequent	as	in	the	HZ-vaccinated	group	(6.6%	vs.	3	
5.7%).	One	of	the	SAEs	in	the	HZ	group	was	vaccine-related	but	the	exact	reason	was	not	mentioned.	4	
Six	deaths	occurred	(three	in	placebo	group	and	three	in	HZ	group),	of	which	none	was	judged	to	be	5	
vaccine-related.	 The	 most	 frequently	 reported	 SAEs	 were	 respiratory,	 thoracic	 and	 mediastinal	6	
disorders	[12].		7	
After	 receiving	MMR,	poliomyelitis,	 small	pox,	 live	 typhoid	and	BCG	vaccination	 in	 the	 IMID	group,	8	
there	were	no	 reported	SAEs.	 Similarly,	 in	 the	SOT	and	BMT	group	no	SAEs	were	 reported.	Across	9	
IMID,	SOT	and	BMT	patients,	17	articles	did	not	document	whether	adverse	events	were	observed.		10	
Pathology	through	unrestricted	proliferation	of	the	attenuated	strain		11	
	12	
32	 participants	 developed	 an	 infection	 through	 the	 vaccine	 strain.	 Overall,	 one	 infection	 occurred	13	
after	YFV,	 three	after	MMR	vaccination,	20	after	VV,	 five	after	HZV,	one	after	 live	polio,	 one	after	14	
BCG,	and	one	after	smallpox	vaccination.	15	
	16	
IMID	17	
In	12	of	20,556	(0.06%)	IMID	patients	a	vaccine-strain-related	infection	was	reported	(Table	3).	One	18	
49-year	 old	 female	 patient	with	 rheumatoid	 arthritis	 (RA)	 and	 systemic	 lupus	 erythematosus	 (SLE)	19	
who	started	MTX	and	dexamethasone	(dosage	unknown)	four	days	after	the	YFV	developed	a	yellow	20	
fever	 vaccine-associated	 viscerotropic	 disease	 (YEL-AVD)	 and	 died	 [13,14].	 She	 received	 the	21	
vaccination	during	 a	 YF	 vaccination	 campaign	 in	 Peru,	 during	which	one	particular	 vaccine	 lot	was	22	
found	 to	 be	 associated	 with	 a	 more	 than	 20	 times	 risk	 of	 YEL-AVD.	 Among	 42,742	 persons	 who	23	
received	a	vaccine	from	this	lot,	five	developed	a	YEL-AVD.		24	
One	juvenile	idiopathic	arthritis	(JIA)	patient	with	MTX	experienced	a	rash	and	fever	20	days	after	a	25	
	 14	
primary	 MMR	 vaccination	 [15].	 However,	 the	 rash	 was	 interpreted	 as	 disease-related	 [personal	1	
communication	with	authors].		2	
One	 patient	 with	 muco-cutaneous	 lymphnode	 syndrome	 under	 steroid	 therapy	 developed	 mild	3	
varicella	11	days	after	 immunization	with	VV	[16],	one	SLE	patient	experienced	a	 localized	rash	(<5	4	
vesicles)	after	VV	[17].		5	
HZ	and	varicella	 zoster	virus	 (VZV)-like	 rashes	were	seen	 in	 five	patients	after	 immunization	with	a	6	
HZV	 [10,12,18].	One	 of	 them	experienced	 a	 serious	 ophthalmic	 herpes	 zoster	 infection	which	was	7	
determined	to	be	vaccine-related	by	the	investigator;	however	wild	type	virus	and	not	vaccine	strain	8	
virus	was	 identified	by	PCR	 [12].	Another	patient	who	 received	a	15-day	 supply	of	prednisone	 two	9	
months	before	being	vaccinated,	developed	HZ	seven	days	after	vaccination	[18].	One	patient	with	10	
reactive	arthritis	under	50mg	etanercept	had	a	positive	stool	culture	for	poliovirus	Sabin	1-like	RNA	11	
but	without	 any	 symptoms	 after	 oral	 polio	 vaccination	 [19].	 One	 infant	whose	mother	was	 under	12	
infliximab	(IFX)	treatment	during	pregnancy	received	the	BCG	vaccine	at	the	age	of	three	months	and	13	
developed	disseminated	BCG	infection	and	died	[20].	One	patient	with	atopic	eczema	under	topical	14	
fluocinolone	 or	 betamethasone	 therapy	 developed	 smallpox-like	 vesicles	 after	 the	 smallpox	15	
immunization	and	improved	rapidly	after	receiving	hyperimmune	serum	against	vaccinia	[21].	16	
SOT		17	
16/339	(4.7%)	SOT	patients	had	a	vaccine-related	infection	(Table	3);	14	patients	developed	varicella	18	
after	VV	within	two	to	eight	weeks.	In	all	14	patients	it	was	only	a	moderate	form	of	varicella	without	19	
complications	 [22–24].	 Two	 patients	 had	 transient	 swelling	 of	 the	 parotid	 glands	 after	 mumps	20	
immunization	[25,26].		21	
BMT	22	
In	the	BMT	group	one	patient	developed	HZ	seven	days	after	receiving	the	varicella	vaccine	(Table	3)	23	
[27].	Symptoms	resolved	with	treatment.	In	another	study	three	patients	developed	a	disseminated	24	
rash	within	2.5	weeks	after	VV	[28].	The	rash	resolved	without	treatment.	In	all	four	cases	there	was	25	
	 15	
not	clear	whether	the	reaction	had	occurred	in	patients	vaccinated	less	than	or	more	than	two	years	1	
after	BMT.	2	
Flare	of	underlying	disease/	transplant	rejection	after	vaccination	3	
IMID	4	
In	a	self-controlled	case-series	study,	a	12.8	times	(95%CI	4.28-38.13,	p<0.001)	higher	exacerbation	5	
rate	was	reported	in	multiple	sclerosis	(MS)	patients	who	received	YFV	under	glatiramer	acetate	and	6	
interferon	treatment	compared	to	time	periods	when	these	patients	had	not	received	YFV	(“not-at-7	
risk-periods”)	 [29].	 In	a	 retrospective	cohort	 study	by	Heijstek	et	al	 [30],	no	aggravation	of	disease	8	
was	registered	in	the	MMR	vaccinated	JIA	patients.	In	another	study	by	Heijstek	and	colleagues	[31],	9	
the	 mean	 number	 of	 flares	 per	 patient	 did	 also	 not	 differ	 significantly	 between	 the	 vaccinated	10	
patients	and	the	control	group.	A	boy	with	atopic	dermatitis	experienced	an	exacerbation	of	the	skin	11	
disease	 one	 week	 after	 BCG	 vaccination	 [32].	 The	 exacerbation	 of	 the	 skin	 lesions	 resolved	 3.5	12	
months	 later	 after	 treatment.	 While	 1/10	 patients	 with	 inflammatory	 bowel	 disease	 (IBD)	 under	13	
prednisolone	 10mg	 had	 a	 flare	 15	 days	 after	 live	 typhoid	 immunization,	 8/10	 patients	 reported	14	
improvement	of	 abdominal	 symptoms	after	 90	days	 [33].	 In	 three	 further	 studies	 improvement	of	15	
the	 basic	 diseases	 were	 reported.	 Two	 randomized	 controlled	 studies	 mentioned	 a	 significant	16	
improvement	of	 the	psoriatic	area	 in	83%	of	psoriasis	patients	after	 four	doses	of	VV	 [34,35].	 Less	17	
patients	 in	 the	control	group	showed	a	significant	 improvement.	 In	a	case	report,	 two	SLE	patients	18	
experienced	improvement	of	their	extrarenal	manifestations	after	BCG	vaccination	[36].		19	
SOT	20	
In	the	SOT	group,	three	cases	of	organ	rejections	were	reported.	One	patient	developed	an	episode	21	
of	acute	rejection	three	weeks	after	measles	vaccination.	The	other	patient	showed	chronic	rejection	22	
at	 the	 time	 of	 vaccination	 and	 remained	 unchanged	 for	 one	 year	 [37].	 Another	 single	 rejection	23	
episode	of	the	liver	was	reported,	which	occurred	more	than	one	year	after	a	VV	and	was	considered	24	
as	unassociated	to	immunization	[38].		25	
	 16	
BMT	1	
One	child	after	autologous	BMT	had	a	relapse	of	her	malignancy	after	MMR	immunization,	the	time	2	
point	was	unknown	[39].		3	
Immunogenicity	4	
In	43	studies	an	immunogenicity	assessment	was	performed:	23	(YF	n=6,	MMR	n=3,	VV	n=9,	HZ	n=5)	5	
in	the	IMID	group,	12	(YF	n=1,	MMR	n=7,	VV	n=4)	in	the	SOT	group	and	in	all	eight	studies	(MMR	n=3,	6	
VV	n=5)	 in	 the	BMT	group.	 In	 the	majority,	 an	 immunogenicity	 assessment	was	 performed	before	7	
vaccination;	the	time	points	for	the	immunogenicity	assessment	varied	from	15	days	to	13	years	after	8	
vaccination.		9	
	10	
IMID		11	
In	19	articles	 the	humoral	 immune	response	and	 in	 two	articles	 the	humoral	and	cellular	 response	12	
was	assessed.	In	two	articles	the	test	method	was	not	documented.	13	
YF-vaccinated	 IMID	patients	showed	high	seroconversion	rates	 in	 four	articles,	which	did	not	differ	14	
between	 patients	 and	 controls	 [29,40–42].	 Patients	 under	 therapy	 with	 short-term	 high	 dose	15	
corticosteroids,	long-term	low-dose	corticosteroids,	glatiramer	acetate,	interferon	gamma	(INF-y)	or	16	
MTX	 received	 a	 primary	 YFV.	 Only	 in	 one	 of	 these	 studies,	 patients	who	 received	 transcutaneous	17	
vaccination	instead	of	subcutaneous	vaccination	demonstrated	significantly	lower	YFV-specific	T-cell	18	
responses	[40].	After	YF	revaccination	under	 IFX	(±MTX),	1/17	patients	and	1/15	controls	remained	19	
seronegative	[8].	In	another	study	on	rheumatic	patients	under	various	treatments	a	seropositivity	of	20	
87%	was	achieved	after	YF	revaccination.	Patients	showed	lower	titers	of	neutralizing	antibodies	than	21	
healthy	 individuals	 [43].	 The	 patient	 with	 the	 lowest	 antibody	 titer	 had	 been	 administered	 2mg	22	
rituximab	(RTX)	four	months	before	YF	revaccination.	23	
	24	
In	 one	 study,	MMR-vaccinated	 JIA	 patients	 treated	 with	 low-dose	MTX	 had	 lower	 levels	 of	 virus-25	
specific	antibodies	and	IFN-y	producing	T	memory	cells	than	healthy	children	[44].	The	patients	who	26	
	 17	
additionally	 received	etanercept	 showed	a	decline	of	 virus-specific	 IFN-y	producing	 T	 cells	 and	 IgG	1	
antibodies	 were	 slightly	 increased.	 Kawasaki	 patients	 vaccinated	 against	 MMR	 within	 six	 months	2	
after	 administration	 of	 intravenous	 immunoglobulin	 (IVIG)	 had	 lower	 IgG	 concentrations	 against	3	
measles,	mumps	and	rubella	compared	to	controls	[45].	Patients	vaccinated	later	than	nine	months	4	
after	 IVIG	 administration	 did	 not	 show	 any	 difference	 to	 controls.	 No	 significant	 differences	 in	5	
humoral	responses	were	observed	between	patients	with	and	without	MTX	or	biologics	after	MMR	6	
vaccination	[31].	7	
	8	
In	three	studies	with	a	limited	sample	size,	VV	showed	good	immunogenicity	results	in	IMID	patients	9	
[16,46,47].	 In	 two	 studies,	 SLE	 patients	 developed	 comparable	 VZV-specific	 antibody	 levels	 to	10	
controls	[17,48].	However	the	cellular	responses	were	lower	in	SLE	patients	[17].		11	
In	 three	 studies	 JIA	 showed	 lower	 seroconversion	 rates	 than	 controls	 [49–51].	 In	 one	 study	 all	 10	12	
non-converters	 were	 under	 sole	 MTX	 therapy	 or	 received	 additional	 prednisone	 [49].	 In	 another	13	
study	 all	 four	 non-converters	 were	 under	 tumor	 necrosis	 factor	 inhibitor	 (TNFi)	 therapy	 [49].	 In	14	
contrary	 to	 tocilizumab	 (TCZ)	 treated	 patients,	 patients	 under	 IFX/MTX	 and	 etanercept	 had	15	
insufficient	responses	[51].	 In	a	report	of	six	cases	under	treatment	with	mesalamine,	olsalazine,	6-16	
mercaptopurine,	and/or	IFX	extremely	varying	results	were	observed	[52].		17	
	18	
In	three	studies	HZV	showed	a	worse	 immune	response	 in	 immunosuppressed	patients	 than	 in	the	19	
immunocompetent	 group	 [53–55].	 In	 a	 case	 report	 a	 patient	with	MS	 under	 fingolimod	 remained	20	
seronegative	after	administration	of	HZV,	even	despite	he	had	two	clinical	episodes	of	HZ	 infection	21	
[54].		22	
In	 a	 study	 10	 SLE	 patients	 under	 prednisone,	 hydroxychloroquine	 or	MTX	 showed	 similar	 cellular	23	
immune	 responses	 as	 controls,	 but	 the	 increase	 of	 antibody	 levels	was	 lower	 [55].	 In	 two	 studies	24	
patients	 under	 treatment	with	 steroids	 and	 further	modifying	 agents	 achieved	 adequate	 antibody	25	
levels	after	HZV	[12,56].		26	
	 18	
SOT		1	
In	10	studies	 the	humoral	and	 in	 two	studies	cellular	and	humoral	 tests	were	performed.	A	kidney	2	
transplant	 recipient	 under	 CSA	 and	 mycophenolic	 acid	 vaccinated	 against	 YFV	 19	 years	 post-3	
transplant	reached	antibody	titers	within	the	lower	range	of	those	of	controls	[57].		4	
The	 seroconversion	 after	 post-transplant	 vaccination	 showed	 generally	 higher	 rates	 for	 rubella	5	
(range	 70-100%)	 than	 for	measles	 (44-100%),	mumps	 (48-100%)	 and	 varicella	 (71%)	 [25,26,37,58–6	
61].	Patients	were	under	various	therapies	including	CSA,	prednisone,	azathioprine	and	TAC.	In	two	7	
studies,	 the	 patients	 were	 also	 tested	 after	 a	 second	 or	 a	 third	 vaccination	 and	 showed	 higher	8	
seroconversion	rates	afterwards	[58,59].		9	
	10	
The	seroconversion	rate	after	VV	in	SOT	patients	varied	from	25	to	87%	[22,25,26,58–60,62,63].	In	a	11	
study	with	patients	under	triple	therapy	with	prednisone,	CSA	and	azathioprine,	59%	developed	anti-12	
varicella	antibodies	within	the	first	four	to	eight	weeks	after	a	primary	vaccine	dose	[62].	By	three	to	13	
six	months	after	immunization,	85%	were	seropositive	and	at	24	months	76%	of	the	antibody	titers	14	
remained	positive.	 In	 two	studies,	patients	under	MMF,	prednisone,	CSA,	TAC	or	sirolimus	reached	15	
similar	 seroconversion	 rates	 of	 64-67%	 [60,63].	 87%	of	 patients	 under	 CSA	 and	 TAC	 receiving	 one	16	
dose	of	VV	seroconverted	and	86%	had	positive	cellular	responses	[22].		17	
Patients	under	TAC	and	CSA	receiving	a	varicella	 revaccination	one	year	after	 liver	 transplantation,	18	
had	seroconversion	rates	between	50%	and	81%	after	re-immunization	[26,58,59].	19	
In	a	study	all	children	(100%)	reached	seroconversion	after	one,	two	or	three	vaccinations	[38].	After	20	
the	 last	 vaccine	 dose	 96.8%	 (31/32)	 of	 the	 children	 retained	 high-median	 antibody	 titers.	 In	 20	21	
patients,	VZV-specific	CD4+	T	cell	 responses	were	compared	pre-	and	post-	 immunization	and	they	22	
showed	a	significant	increase.	23	
	24	
BMT	25	
In	 four	 studies	 an	 immunogenicity	 assessment	 was	 performed	 by	 humoral	 tests,	 in	 one	 study	 by	26	
	 19	
cellular	 tests	 and	 in	 one	 study	 by	 humoral	 and	 cellular	 tests.	 In	 two	 BMT	 studies	 the	 test	 was	1	
unspecified.		2	
Three	 studies	 with	 patients	 who	 received	 an	 MMR	 immunization	 within	 24	 months	 after	 BMT	3	
showed	a	higher	 seroconversion	 rate	 for	 rubella	 (86-100%)	 than	 for	measles	 (33-46%)	and	mumps	4	
(29-80%)	[11,39,64].	It	was	observed	that	children	seroconverted	more	frequently	to	measles	if	they	5	
were	 immunized	more	 than	15	months	after	BMT	(35%	prior	 to	versus	78%	after	15	months)	 [64].	6	
Seroconversion	rates	were	86%	for	rubella,	43%	for	measles	and	29%	for	mumps	in	patients	treated	7	
with	calcineurin	inhibitors	and	MMF	after	a	primary	MMR	vaccine	[11].	8	
In	another	study,	after	a	primary	measles	vaccine	dose,	all	patients	seroconverted	and	78%	remained	9	
seropositive	 for	 at	 least	 12	 months	 [65].	 However,	 only	 44%	 of	 these	 patients	 were	 on	10	
immunosuppressive	drugs	at	the	time	of	vaccination.		11	
For	varicella	vaccination	after	BMT,	seroconversion	rates	varied	between	33	and	89%	after	a	primary	12	
VV	[11,27,66,67].	In	the	study	in	which	only	33%	seroconversion	was	achieved,	patients	were	under	13	
GvHD-prophylaxis	with	 calcineurin	 inhibitors	 and	MMF.	 In	 the	other	 studies	patients	were	without	14	
immunosuppressive	treatment.		15	
	16	
Clinical	protection	of	vaccines	17	
In	 the	 IMID	 group,	 12/202	 patients	 (6%)	 who	 received	 a	 VV	 nevertheless	 developed	 a	 varicella	18	
infection	 or	 HZ.	 8/19,630	 patients	 (0.04%)	 receiving	 a	 HZV	 later	 had	 a	 HZ	 infection	 despite	19	
vaccination.	YF-,	MMR-,	Polio,	BCG-	and	typhoid	fever-vaccinated	patients	appeared	to	be	protected	20	
and	did	not	develop	an	infection.		21	
In	 the	 SOT	 group,	 7/192	 (3.6%)	 patients	 developed	 a	 varicella	 infection	 despite	 being	 vaccinated	22	
against	varicella.			2/38	(5.3%)	in	the	BMT	group	developed	varicella	in	spite	of	a	VV.	Patients	in	the	23	
SOT	 and	 BMT	 group	 who	 were	 vaccinated	 against	 YF,	 MMR	 and	 BCG	 were	 protected	 against	24	
infection.	Follow-up	periods	for	clinical	protection	varied	between	6	weeks	to	12.5	years.	25	
	 	26	
	 20	
Discussion	1	
Whether	 live	 vaccines	 can	 be	 administered	 to	 immunocompromised	 patients	 is	 an	 often-2	
encountered	 problem	 by	 physicians	 caring	 for	 this	 specific	 patient	 group.	 On	 the	 one	 hand	 these	3	
patients	are	especially	vulnerable	from	infections	(many	of	them	vaccine-preventable)	on	the	other	4	
hand	there	is	a	potential	risk	of	harming	the	patient	by	the	administration	of	a	vaccine	containing	an	5	
attenuated	 vaccine	 strain,	which	 has	 the	 theoretical	 potential	 to	 revert	 to	 the	 original	 pathogenic	6	
form	 and	 to	 induce	 infection	 in	 the	 immunocompromised	 individual.	 Apart	 from	 infecting	 the	7	
immunocompromised	 person,	 more	 vaccine-related	 side	 effects	 as	 well	 as	 re-activation	 of	 the	8	
underlying	 disease	 is	 feared.	 Therefore	 this	 review	 summarizes	 available	 information	 in	 order	 to	9	
inform	 the	 practitioner	 of	 currently	 available	 evidence	 by	 reviewing	 and	 giving	 an	 overview	 on	10	
currently	available	literature	on	this	topic.	11	
Generally	local	and	systemic	reactions	were	mild.	While	they	were	rare	in	IMID	patients	(prevalence	12	
of	 1%),	 they	 occurred	 more	 frequently	 in	 BMT	 (6%)	 and	 SOT	 patients	 (18%).	 The	 percentages	 of	13	
adverse	events	(AEs)	appear	low	compared	to	AEs	reported	in	the	general	population	[68–71].	This	is	14	
most	likely	due	to	underreporting	of	AEs	in	our	included	studies.		15	
Altogether,	 11	 SAEs	 due	 to	 local	 or	 systemic	 reactions	 including	 three	 deaths	 were	 reported;	16	
however,	 none	 of	 the	 deaths	was	 vaccine-associated.	 All	 reported	 SAEs	 occurred	 in	 IMID	 patients	17	
after	HZV.	 In	the	other	vaccination	groups,	numbers	of	patients	were	 low,	thus	SAEs	may	not	have	18	
been	observed	due	to	the	limited	sample	sizes.	Also	in	the	literature	local	or	systemic	SAEs	after	live	19	
vaccinations	 are	 extremely	 rare.	 For	 examples,	 anaphylactic	 reactions	 after	 YFV	 occur	 in	 0.8-20	
1.8/100,000	administered	doses	and	thrombocytopenia	after	MMR	vaccination	is	estimated	to	occur	21	
in	one	out	of	30,000-40,000	administered	MMR	doses	[72,73].	22	
In	the	2010	published	recommendations	on	YFV	on	immunization	practices	of	the	Centers	for	Disease	23	
Control	and	Prevention	report	on	several	YEL-AVD	cases	in	individuals	with	underlying	autoimmune	24	
conditions:	three	patients	with	SLE,	two	with	Addison's	disease,	one	with	Crohn's	disease,	one	with	25	
	 21	
polymyalgia	 rheumatica	 and	 hypothyroidsm,	 one	 with	 ulcerative	 colitis,	 and	 one	 with	myasthenia	1	
gravis	 [74].	 In	 direct	 correspondence	 with	 one	 of	 the	 authors,	 she	 confirmed	 that	 a	 number	 of	2	
viscerotropic	diseases	have	occurred	in	persons	with	autoimmune	diseases.	However,	it	could	not	be	3	
clarified	whether	these	patients	were	on	immunosuppressive	or	immunomodulatory	therapy	at	the	4	
time	of	YFV.	Thus,	it	remains	unclear	how	to	interpret	this	information.	The	safety	monitoring	board	5	
in	 Switzerland	 has	 not	 detected	 a	 severe	 infection	with	 a	 vaccine	 strain	 in	 an	 immunosuppressed	6	
patient	between	2001	and	May	2016	[personal	communication].		7	
Infections	 through	 vaccine	 strains	 were	 extremely	 rare.	 However,	 two	 of	 them	were	 deadly.	 One	8	
occurred	 in	 a	patient	with	RA/SLE	overlap	who	 received	YFV	 four	days	prior	 to	 commencement	of	9	
MTX/dexamethasone	 treatment.	 However,	 the	 administered	 vaccine	 lot	 was	 associated	with	 a	 20	10	
times	 higher	 risk	 of	 YEL-AVD	 compared	 to	 other	 YFV	 lots.	 A	 fatal	 disseminated	 BCG	 infection	was	11	
reported	upon	vaccination	of	a	three-month-old	infant	born	to	a	mother	under	IFX	treatment.	Thus,	12	
infants	born	 to	 immunosuppressed	mothers	 should	be	vaccinated	with	caution.	The	other	vaccine-13	
associated	infections	were	either	self-limiting	or	resolved	upon	treatment.	14	
Regarding	 reactivation	 of	 the	 underlying	 disease,	 apart	 from	 one	 article,	 no	 increase	 of	 flares	 of	15	
underlying	 autoimmune	 conditions	 was	 encountered.	 One	 study	 detected	 a	 more	 than	 12	 times	16	
elevated	risk	of	MS	exacerbation	after	YFV	[29].	However,	this	self-controlled	case	series	study	was	17	
criticized	for	methodological	issues	[75].	18	
In	SOT	patients,	one	 liver	 transplant	 rejection	was	 reported	 three	weeks	after	measles	vaccination	19	
[37].	Acute	organ	rejections	can	occur	in	around	15-25%	of	liver	transplant	recipients	[76–78].	Thus	it	20	
is	not	surprising	to	see	an	acute	organ	rejection	three	weeks	after	measles	vaccination	(one	of	271	21	
liver	transplant	patients	who	received	a	live	vaccine),	which	is	most	likely	only	timely	but	not	causally	22	
associated	 to	 vaccination.	 Details	 such	 as	 numbers	 on	 non-serious	 specific	 systemic	 and	 local	23	
reactions	were	often	not	presented	in	the	publications.	24	
	25	
	 22	
Immunogenicity	 data	 are	 difficult	 to	 interpret	 as	 a	 large	 variety	 of	 serological	 and	 cellular	 test	1	
methods	were	used.	YF	(re)vaccinations	appeared	to	be	 immunogenic	 in	most	patient	groups.	TNFi	2	
and	MTX	therapy	seemed	to	 reduce	 immune	responses	after	VV	and	HZ	vaccination.	This	 is	 in	 line	3	
with	studies	on	inactivated	vaccines,	such	as	pneumococcal	and	hepatitis	A	vaccine	[79,80].	Rubella	4	
vaccinations	 appeared	 more	 immunogenic	 than	 measles	 and	 mumps	 vaccination,	 which	 is	 also	5	
known	in	non-immunosuppressed	individuals	[73].		For	VV,	one	vaccine	did	often	not	suffice,	but	two	6	
or	more	vaccine	doses	generally	conferred	satisfactory	immunity.	7	
Most	studies	 included	in	this	systematic	review	were	conducted	in	a	non-randomized,	uncontrolled	8	
and	unblinded	way	and	thus	are	prone	to	bias.	Only	eight	of	64	included	studies	were	RCTs.	Only	in	9	
one	 study	 blinding	 of	 patients	 and	 study	 personnel	 was	 performed.	 However,	 as	 literature	 is	10	
generally	 scarce	 on	 live	 vaccines	 in	 the	 immunosuppressed	we	 included	 observational	 studies	 and	11	
case	 reports	 as	 our	 aim	 was	 to	 compile	 all	 available	 evidence	 on	 live	 vaccinations	 in	12	
immunosuppressed	IMID,	SOT	patients	as	well	as	BMT	patients	who	received	a	live	vaccine	less	than	13	
two	 years	 after	 transplantation.	 Furthermore,	 this	 systematic	 review	 may	 have	 missed	 published	14	
studies	as	the	search	was	conducted	in	English.	Even	though	we	included	grey	literature,	publication	15	
bias	may	have	limited	the	identifiable	studies/case	reports.	16	
	17	
A	YEL-AVD	occurs	 in	an	estimated	0.4	of	100,000	administered	vaccine	doses	[81].	 In	our	 identified	18	
studies	 and	 case	 reports	 we	 found	 one	 YEL-AVD	 in	 a	 RA/SLE	 patient	 who	 was	 vaccinated	 with	 a	19	
specific	vaccine	strain	associated	with	a	higher	YEL-AVD	risk.	 It	 is	well	possible	that	more	YEL-AVDs	20	
were	 simply	 missed/or	 have	 not	 occurred	 as	 patient	 numbers	 who	 received	 a	 live	 vaccine	 are	21	
extremely	 low.	Severe	reactions	or	 infections	may	only	be	discovered	 if	a	 large	number	of	patients	22	
with	these	conditions	receive	live	vaccines.		23	
	24	
	25	
	26	
	 23	
Conclusion	1	
Overall,	 the	 identified	 data	 on	 live	 vaccinations	 in	 IMID	 and	 SOT	 patients	 on	 immunosuppressive	2	
treatment	as	well	as	patients	less	than	two	years	after	BMT	are	not	sufficiently	robust	to	change	the	3	
currently	available	international	vaccination	recommendations	which	generally	are	very	restrictive	on	4	
live	vaccines	under	immunosuppression	or	shortly	after	BMT.	Only	eight	randomized	controlled	trials	5	
could	be	identified	and	all	were	conducted	in	IMID	patients.	However,	patient	groups,	medications,	6	
medication	dosages	and	live	vaccinations	were	diverse	within	these	eight	trials	and	generally	patient	7	
numbers	were	low.	8	
From	 the	 available	 evidence	 we	 cannot	 conclude	 that	 live	 vaccines	 are	 safe	 altogether	 in	9	
immunosuppressed	IMID,	SOT	and	when	administered	within	two	years	after	BMT.	However,	despite	10	
the	 limitations	 discussed	 above	 it	 is	 re-assuring	 that	 in	 the	 examined	 patient	 groups	 serious	 side	11	
effects	 or	 infections	 by	 the	 attenuated	 vaccine	 strain	 were	 extremely	 scarce	 after	 primary	12	
vaccinations	and	revaccinations	with	the	examined	vaccines	(MMR,	YFV,	VV,	HZV,	oral	typhoid	fever,	13	
oral	polio,	BCG,	smallpox).	14	
We	 believe	 that	 our	 research	 of	 the	 existing	 literature	 is	 of	 help	 to	 the	 interested	 specialist	15	
confronted	with	the	decision	process	on	whether	to	vaccinate	an	immunosuppressed	patient.	More	16	
evidence	 regarding	 the	 safety	 and	 immunogenicity	 of	 live	 vaccinations	 in	 IMID	 and	 SOT	 patients	17	
under	various	 immunosuppressive	therapies	as	well	as	 in	patients	 less	 than	two	years	after	BMT	 is	18	
urgently	 needed.	 Vaccination	 recommendations	 need	 to	 be	 adapted	 on	 a	 regular	 basis,	 as	 more	19	
scientific	 data	 regarding	 vaccination	 safety	 and	 efficacy,	 new	 vaccines	 as	 well	 as	 new	20	
immunosuppressive	therapies	will	become	available.	21	
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